Acacia Pharma Group plc
Acacia Pharma Group plc
05/25/2021 | Press release | Distributed by Public on 05/25/2021 10:02
Acacia Pharma Group plc: Notice of Annual General Meeting
Acacia Pharma Group plc: Notice of Annual General Meeting
Cambridge, UK and Indianapolis, US - 25 May 2021 Acacia Pharma Group plc ('Acacia Pharma', the 'Company') (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that its annual general meeting of shareholders ('AGM') will be held at 2:00pm BST on Monday 28 June 2021 at the offices of Acacia Pharma Inc, 8440 Allison Pointe Boulevard, Suite 100, Indianapolis, IN 46250, United States.
The formal notice convening the AGM (including agenda, information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting) together with the Form of Proxy, and the Company's Annual Report and Accounts for the year ended 31 December 2020, will be posted to shareholders today and are available from today on the Company's website www.acaciapharma.com in the Investors/Shareholder Meetings section and the Investors/Financial Reports section, respectively.
Contacts
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.
Acacia Pharma's first product, BARHEMSYS® (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).
BYFAVO™ (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved and launched in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.
Acacia Pharma Group plc
The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United Kingdom
Company number 9759376